Pharmasol (Pvt) Ltd.
Private pharmaceutical manufacturer · Lahore · Pakistan
Lahore-based pharmaceutical manufacturer with a purpose-built cGMP facility covering multiple specialized dosage-form and therapeutic sections.
What is sourced, and how recent is it?
Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.
Company profile
- Company type
- Private pharmaceutical manufacturer
- Address
- 82, R-1, M.A. Johar Town, Lahore-54100, Pakistan · 54100
- Website
- pharmasol.com.pk ↗
- Phone
- +92 42 111 773 227
- Official contact
- Contact page ↗
- Official company profile ↗
- Corporate source details checked
- 16 Aug 2026
- Corporate profile completeness
- 100%
Company location
A sourced company location is recorded. Use the map link below for directions.
Portfolio at a glance
RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.
PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.
IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.
Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.
Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.
Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.
How complete is this profile?
Downloadable company intelligence charts
Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.
Therapeutic Portfolio Mix
Shows where the company portfolio is concentrated across broad therapeutic areas.
Portfolio distribution, not sales or market-share data.
Dosage Form Portfolio
Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.
Counts are product presentations, not production or sales volumes.
Equivalent Price Position
Shows whether safely comparable products are below, near or above the peer median unit price.
This is price-position intelligence, not sales, demand or market-share data.
Closest Portfolio Competitors
Highlights other manufacturers with the greatest generic overlap with this company portfolio.
Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.
Therapeutic areas
High-level clinical areas represented by this company’s current MedInfoBase portfolio.
Drug classes
More specific classes derived from the canonical generic and preserved curated classifications.
Dosage forms
How MedInfoBase classifies the portfolio
MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.
Deepest brand families
Unit-price positioning vs equivalent products
How MedInfoBase calculates price position
Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.
Portfolio overlap
Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.
Observed database signals
These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.
Medicine portfolio
This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.
| Brand | Generic | Strength | Form | Pack | Registration | Source-listed price | Unit price | Price position |
|---|---|---|---|---|---|---|---|---|
| Glyfozin | Empagliflozin | 25 mg | Tablet | 14's | 121811 | PKR 1,436.64 | PKR 102.62/tablet | Near median |
| Glynib | Imatinib | 100 mg | Capsule | 120's | 098378 | PKR 122,797.93 | PKR 1,023.32/capsule | 25% above median |
| Glynib | Imatinib | 400 mg | Tablet | 30's | 115441 | PKR 103,265.21 | PKR 3,442.17/tablet | Near median |
| Grafsol | Tacrolimus | 1 mg | Capsule | 50's | 101704 | PKR 4,843.64 | PKR 96.87/capsule | Near median |
| Grafsol | Tacrolimus | 1 mg | Capsule | 10's | 101704 | PKR 1,052.97 | PKR 105.30/capsule | 8% above median |
| Grafsol | Tacrolimus | 1 mg | Capsule | 30's | 101704 | PKR 2,906.19 | PKR 96.87/capsule | Near median |
| Grafsol | Tacrolimus | 0.5 mg | Capsule | 50's | 115443 | PKR 9,603.66 | PKR 192.07/capsule | 236% above median |
| Hicartif | Hydrocortisone | 100 mg | Dry powder for injection | 25's (Additional Pack) | 090493 | PKR 3,401.50 | PKR 136.06/vial/unit | Near median |
| Hicartif | Hydrocortisone | 100 mg | Dry powder for injection | 1's | 090493 | PKR 141.72 | PKR 141.72/vial/unit | Near median |
| Hicartif | Hydrocortisone | 250 mg | Dry powder for injection | 25's (Additional Pack) | 090494 | PKR 5,917.69 | PKR 236.71/vial/unit | Near median |
| Hicartif | Hydrocortisone | 250 mg | Dry powder for injection | 1's | 090494 | PKR 246.57 | PKR 246.57/vial/unit | Near median |
| Hicartif | Hydrocortisone | 500 mg | Dry powder for injection | 25's (Additional Pack) | 090495 | PKR 13,605.35 | PKR 544.21/vial/unit | Near median |
| Hicartif | Hydrocortisone | 500 mg | Dry powder for injection | 1's | 090495 | PKR 566.89 | PKR 566.89/vial/unit | Near median |
| Hydroxa | Hydroxyurea | 500 mg | Capsule | 10's | 091813 | PKR 248.66 | PKR 24.87/capsule | 14% below median |
| Ibrusol | Ibrutinib | 140 mg | Capsule | 12x10's | 136765 | PKR 188,000.00 | PKR 1,566.67/capsule | 24% below median |
| Idokal | Potassium iodide | 130 mg | Tablet | 20's | 104666 | PKR 77.02 | PKR 3.85/tablet | 49% above median |
| Inxamic | Tranexamic acid | 250 mg/5 mL | Injection | 5mlx10's | 089929 | PKR 907.81 | PKR 18.16/mL | 62% above median |
| Inxamic | Tranexamic acid | 500 mg/5 mL | Injection | 10's | 099695 | PKR 1,569.61 | PKR 156.96/vial/unit | Near median |
| Irinosol | Irinotecan | 100 mg/5 mL | Injection | 5ml x 1's Vial | 115661 | PKR 14,212.21 | — | No comparator |
| Ironate | Iron protein succinylate | 800 mg/15 mL (equiv. 40 mg elemental iron) | Syrup | 120ml | 094575 | PKR 332.39 | PKR 2.77/mL | 9% below median |
| Ironate | Iron protein succinylate | 800 mg/5 mL | Syrup | 60ml | 094575 | PKR 175.43 | PKR 2.92/mL | 8% below median |
| Konacane | Fluconazole | 50 mg/5 mL | Suspension | 35ml | 090409 | PKR 407.70 | PKR 11.65/mL | Near median |
| Konacane | Fluconazole | 150 mg | Capsule | 1's | 093126 | PKR 267.92 | PKR 267.92/capsule | Near median |
| Konacane | Fluconazole | 200 mg/100 mL | IV infusion | 100mlx1s | 102577 | PKR 840.20 | PKR 8.40/mL | 7% above median |
| Levoxsel | Levofloxacin | 750 mg | Tablet | 10's | 093129 | PKR 970.73 | PKR 97.07/tablet | Near median |
| Levoxsel | Levofloxacin | 250 mg | Tablet | 10's | 093130 | PKR 485.36 | PKR 48.54/tablet | Near median |
| Levoxsel | Levofloxacin | 250 mg | Tablet | 10 x 10's | 093130 | PKR 4,465.36 | PKR 44.65/tablet | 7% below median |
| Levoxsel | Levofloxacin | 500 mg | Tablet | 10's | 093131 | PKR 807.65 | PKR 80.77/tablet | Near median |
| Levoxsel | Levofloxacin | 500 mg | Tablet | 10 x 10's | 093131 | PKR 7,429.98 | PKR 74.30/tablet | 6% below median |
| Lidosol | Lidocaine | 1 % | Injection | 2ml | 099708 | PKR 12.01 | PKR 6.01/mL | 114% above median |
| M-Floxsel | Moxifloxacin | 400 mg | Tablet | 10 x 10's | 093132 | PKR 16,968.39 | PKR 169.68/tablet | 8% below median |
| M-Floxsel | Moxifloxacin | 400 mg | Tablet | 1 x 5's | 093132 | PKR 922.20 | PKR 184.44/tablet | Near median |
| Medoxol | Metronidazole | 500 mg/100 mL | Injection | 100ml | 100861 | PKR 189.93 | PKR 1.90/mL | 38% above median |
| Medroxin | Methylprednisolone | 40 mg/mL | Injectable suspension | 1's vial | 090489 | PKR 203.85 | PKR 203.85/unit | No comparator |
| Merosol | Meropenem | 500 mg | Injection | 1's | 089930 | PKR 2,077.37 | PKR 2,077.37/vial/unit | Near median |
| Merosol | Meropenem | 1 g | IV injection | 1's | 089931 | PKR 3,964.25 | PKR 3,964.25/vial/unit | Near median |
| Mesdon | Risperidone | 1 mg | Tablet | 10's | 106216 | PKR 207.09 | PKR 20.71/tablet | 11% below median |
| Mesdon | Risperidone | 2 mg | Tablet | 10's | 106217 | PKR 336.53 | PKR 33.65/tablet | 9% below median |
| Mesdon | Risperidone | 3 mg | Tablet | 10's | 106218 | PKR 517.73 | PKR 51.77/tablet | 11% below median |
| Mesdon | Risperidone | 4 mg | Tablet | 10's | 106219 | PKR 673.05 | PKR 67.31/tablet | 8% below median |
| Methrix Lotion | Permethrin | 50 mg/g | Lotion | 60ml | 089897 | PKR 180.84 | PKR 3.01/mL | No comparator |
| Micogel Oral | Miconazole | 20 mg/g | Gel | 20gm | 091432 | PKR 168.48 | PKR 8.42/g | Near median |
| Molta | Paracetamol | 1 g | IV infusion | 100mlx1's | 087513 | PKR 147.43 | PKR 1.47/mL | 5% above median |
| Monozole | Clotrimazole | 10 mg/mL | Lotion | 30ml | 089905 | PKR 59.46 | PKR 1.98/mL | 6% below median |
| Nastozol | Anastrozole | 1 mg | Tablet | 28's | 091810 | PKR 9,295.73 | PKR 331.99/tablet | Near median |
| Natasol | Natamycin | 50 mg/mL | Suspension | 15ml | 099704 | PKR 323.16 | PKR 21.54/mL | 32% above median |
| Nautant | Aprepitant | 40 mg | Capsule | 2's | 099668 | PKR 1,791.20 | PKR 895.60/capsule | Near median |
| Nautant | Aprepitant | 125 mg | Capsule | 2's | 099670 | PKR 4,671.87 | PKR 2,335.94/capsule | Near median |
| Nautant | Aprepitant | 125 mg | Capsule | 1's | 099670 | PKR 2,335.93 | PKR 2,335.93/capsule | Near median |
| Nitonib | Nilotinib | 150 mg | Capsule | 120's | 094596 | PKR 280,817.09 | PKR 2,340.14/capsule | Near median |
MedInfoBase company-intelligence methodology
This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.
Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.
Cite this record
Manufacturer recordRecords change over time. Please cite the access date so readers can locate the version you used.